Aprea Therapeutics, Inc. (APRE)
NASDAQ: APRE · Real-Time Price · USD
0.9146
+0.0046 (0.51%)
At close: May 27, 2026, 4:00 PM EDT
0.9146
0.00 (0.00%)
After-hours: May 27, 2026, 4:00 PM EDT
Aprea Therapeutics Revenue
Aprea Therapeutics had revenue of $123.30K in the twelve months ending March 31, 2026, down -90.40% year-over-year. In the year 2025, Aprea Therapeutics had annual revenue of $285.76K, down -80.98%.
Revenue (ttm)
$123.30K
Revenue Growth
-90.40%
P/S Ratio
87.54
Revenue / Employee
$15,412
Employees
8
Market Cap
10.96M
Revenue Chart
Revenue History
| Fiscal Year End | Revenue | Change | Growth |
|---|---|---|---|
| Dec 31, 2025 | 285.76K | -1.22M | -80.98% |
| Dec 31, 2024 | 1.50M | 919.35K | 157.63% |
| Dec 31, 2023 | 583.23K | - | - |
| Dec 31, 2022 | - | - | - |
| Dec 31, 2021 | - | - | - |
| Dec 31, 2020 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
Revenue Definition
Revenue, also called sales, is the amount of money a company receives from its business activities, such as sales of products or services. Revenue does not take any expenses into account and is therefore different from profits.
Full DefinitionRelated Stocks
| Company Name | Revenue |
|---|---|
| BioLineRx | 1.18M |
| GeoVax Labs | 852.28K |
| Jupiter Neurosciences | 40.45K |
| Kiora Pharmaceuticals | 20.00K |
| BioCardia | 3.00K |
APRE News
- 13 days ago - Aprea Therapeutics price target lowered to $6 from $7 at Wedbush - TheFly
- 14 days ago - Aprea Therapeutics reports Q1 EPS (22c) vs. (66c) last year - TheFly
- 14 days ago - Aprea Therapeutics Earnings release: Q1 2026 - Filings
- 14 days ago - Aprea Therapeutics Quarterly report: Q1 2026 - Filings
- 14 days ago - Aprea Therapeutics Reports First Quarter 2026 Financial Results and Provides a Corporate Update - GlobeNewsWire
- 20 days ago - Aprea Therapeutics initiated with an Outperform at Oppenheimer - TheFly
- 27 days ago - Aprea Therapeutics Proxy statement: Proxy filing - Filings
- 27 days ago - Aprea Therapeutics Proxy statement: Proxy filing - Filings